Although clinical trials of stimulation of angiogenesis by transfection of angiogenic growth factors using naked plas
Introduction
Recent progress in molecular biology has led to the development of gene therapy, as a new treatment strategy for cardiovascular diseases. Targeted diseases range from single gene deficiency diseases to more complex diseases in adults such as peripheral arterial disease. Critical limb ischemia is estimated to develop in 500 to 1000 individuals per million per year. 1 Of importance, there is no optimal medical therapy for critical limb ischemia, 2, 3 on Critical Limb Ischemia concluded. 1 Therefore, novel therapeutic modalities are needed to treat these patients. Recently, the efficacy of therapeutic angiogenesis using VEGF (vascular endothelial growth factor) gene transfer has been reported in human patients with critical limb ischemia [4] [5] [6] [7] and myocardial ischemia. [8] [9] [10] [11] In addition to VEGF, the utility of gene transfer of other angiogenic growth factors such as fibroblast growth factor (FGF) or hepatocyte growth factor (HGF) has been reported to stimulate collateral formation. [12] [13] [14] [15] [16] [17] [18] [19] [20] The feasibility of gene therapy using angiogenic growth factors to treat peripheral arterial disease seems to be superior to recombinant protein therapy for the following reasons: (1) It has the potential to maintain an optimally high and local concentration over time. This issue may be critical in the case of arterial gene therapy. Thus, in the case of therapeutic angiogenesis, it may be preferable to deliver a lower dose over a period of several days or more from an actively expressed transgene in the iliac artery, rather than a single or multiple bolus doses of recombinant protein, to avoid side-effects. (2) Regarding economics, which therapy would ultimately cost more to develop, implement, and reimburse, particularly for those indications requiring multiple or even protracted treatment, needs to be considered. ( 3) The feasibility of a clinical trial of recombinant protein is still limited by the difficulty of approved available quantities of recombinant protein of human quality grade, due in large part to the nearly prohibitive cost of scaling up from research grade to human quality recombinant protein.
Interestingly, most successful clinical trials of treating peripheral arterial disease using angiogenic growth factors have been performed by intramuscular transfection of naked plasmid DNA, [4] [5] [6] [7] [8] although in vivo gene transfer using direct injection of 'naked' DNA into cardiac and skeletal muscle is inefficient. It is apparent that a more efficient gene transfer method is required to achieve therapeutic effects. Recently, many investigators have focused on the adenoviral gene transfer method. 14, 15, 17, [20] [21] [22] [23] [24] [25] [26] Although the adenoviral vector is very efficient, 14, 15, 17, [20] [21] [22] [23] [24] [25] [26] there are some theoretical disadvantages such as strong immunogenicity. 27 In addition to efficiency, safety of the gene transfer method is also an important issue, since infusion of adenovirus has recently been reported to cause deleterious side-effects. 28 In considering an ideal treatment for peripheral arterial disease, it would be desirable to modify nonvirus-mediated plasmid DNA transfection. These innovations of plasmid DNA-based gene transfer should provide the high transfection efficiency without severe side-effects. Thus, we modified the plasmid DNA gene transfer method for successful in vivo gene transfer into the skeletal muscle, as follows: (1) plasmid DNA alone, (2) ultrasound and (3) ultrasound with echo contrast microbubble (Optison), in this study.
Results

Comparison of transfection efficiency into cultured skeletal muscle cells in vitro and rat muscle in vivo
Initially, we compared the transfection efficiency of naked luciferase gene plasmid DNA using three different Gene Therapy methods (naked plasmid DNA alone, plasmid DNA using ultrasound, plasmid DNA using ultrasound with Optison). As shown in Figure 1a , transfection of naked luciferase plasmid DNA exhibited an extremely low level of luciferase activity in cultured skeletal muscle cells (325 ± 51 RLU/dish), whereas transfection of control vector did not demonstrate luciferase activity. Transfection of naked plasmid DNA using ultrasound exhibited a significant increase in luciferase activity (P Ͻ 0.01, Figure  1a) . However, its transfection efficiency was still low. Therefore, we examined the transfection of naked plasmid DNA using ultrasound with Optison, since microbubble may be used as a carrier of plasmid DNA (see Figure 1a) . More than expected, the combination of ultrasound with Optison exhibited a marked increase in luciferase activity of over 7000-fold in cultured muscle cells (10-fold as compared to plasmid with ultrasound; P Ͻ 0.01, Figure 1b) . To confirm the hypothesis, we performed electron microscopic scanning of cells transfected with plasmid DNA using ultrasound with Optison. Initially, we performed electron microscopic scanning of cells transfected with plasmid DNA using ultrasound with Optison. As shown in Figure 1c , immediately after transfection, cells exhibited small holes in the cell surface and eventually returned to a normal appearance within 24 h. It is suspected that ultrasound, irradiation with Optison causes transient holes in the cell surface, thereby resulting in rapid translocation of plasmid DNA from outside into the cytoplasm. Ultrasound alone does not cause the holes as compared with co-administration of Optison. No holes were detected in untransfected cells or cells under Optison alone. There was no apparent cell toxicity in cells transfected with plasmid DNA using ultrasound with Optison. Indeed, there was no significant changes in LDH activity at 24 h after transfection (untransfected: 0.0077 ± 0.0012; ultrasound alone: 0.0057 ± 0.0013; ultrasound + Optison: 0.0053 ± 0.0011, not significant, n = 6). In addition, we examined the transfection efficiency using other microbubbles such as Levovist and sonicated Hexabrix. Among these microbubbles, transfection with Optison demonstrated the highest transfection efficiency into muscle cells (data not shown).
Thus, we further investigated the optimal conditions of naked plasmid DNA transfection using ultrasound with Optison into rat skeletal muscle in vivo, with the aim of achieving clinical gene therapy ( Figure 2a ). Transfection of naked plasmid DNA using ultrasound with Optison demonstrated the highest luciferase activity among plasmid DNA alone, plasmid DNA using ultrasound, and plasmid DNA using ultrasound with Optison (data not shown). First, we examined the effects of the duration of ultrasound on transfection efficiency. The duration of ultrasound from 1 min to 16 min did not affect luciferase activity (Figure 2b ). Thus, we employed a 1 min duration (repeated eight times for 1 min irradiation) in further experiments. Then, we studied the optimal ratio of Optison and plasmid DNA. As shown in Figure 2c , an Optison concentration of 75% exhibited maximum transfection efficiency into rat skeletal muscle as assessed by luciferase activity. Thus, we fixed the concentration of Optison at 75% (plasmid DNA solution: Optison = 1:3) in further analyses. To confirm the transfection efficiency, we employed another marker gene, ␤-galactosidase. As shown in Figure 3 , intramuscular transfection of ␤-galactosidase plasmid DNA using ultrasound with Optison resulted in positive staining of ␤-galactosidase in a wide area of muscle as assessed by immunostaining, whereas no positive staining of ␤-galactosidase was observed in muscle transfected with control vector.
In vivo transfection of plasmid DNA of HGF into rabbit ischemia model
In vitro and in vivo studies demonstrated that transfection of naked plasmid DNA using ultrasound with Optison was efficient in cultured skeletal muscle cells and rat skeletal muscle. However, no report has documented transfection efficiency of a plasmid-based gene transfer method in the rabbit ischemia model. It would be note- worthy to examine therapeutic angiogenesis in the rabbit model, since this model is appropriate for preclinical studies on the treatment of peripheral arterial disease using angiogenic growth factors. Therefore, naked human HGF plasmid was intramuscularly injected into the ischemic hindlimb of rabbits in which the femoral artery was excised to induce unilateral hindlimb ischemia. There was no significant difference in body weight between rabbits treated with HGF plasmid and control vector on day 45 after surgery (data not shown).
Human immunoreactive HGF could be detected even in rabbits transfected with human HGF plasmid DNA alone, but not control vector, at 4 days after transfection (HGF: 2.08 ± 0.39 ng/g tissue; control: not detected, P Ͻ 0.01). Intramuscular injection of HGF plasmid DNA alone into the ischemic limb on day 10 after surgery produced significant augmentation of collateral vessel development as assessed by angiography on day 30 in the ischemia model, as shown in Figure 4a (P Ͻ 0.01). Serial angiograms revealed progressive linear extension of collateral Gene Therapy arteries from the origin stem artery to the distal point of the reconstituted parent vessel in rabbits transfected with plasmid HGF DNA. Intramuscular transfection of plasmid HGF DNA also reduced severe necrosis due to ischemia in rabbit muscle, while rabbits transfected with control vector demonstrated severe muscle necrosis (data not shown). Of importance, intramuscular transfection of plasmid HGF DNA using ultrasound with Optison vector resulted in a significant increase in angiographic score as compared with plasmid HGF DNA alone, consistent with luciferase experiments (Figure 4 , P Ͻ 0.01). Capillary density in the rabbits transfected with plasmid HGF DNA using ultrasound with Optison vector was significantly increased as compared with plasmid HGF DNA alone or plasmid DNA using ultrasound without Optison ( Figure  5a and b, P Ͻ 0.01). Consistent with induction of angiogenesis, a significant increase in blood flow as assessed by a Doppler flow wire under basal conditions was observed in rabbits transfected with HGF plasmid using ultrasound with Optison as compared with rabbits transfected with plasmid HGF DNA alone (Figure 5c , P Ͻ 0.01). Similarly, a significant increase in blood pressure ratio of the ischemic limb to the normal limb was also observed in rabbits transfected with HGF plasmid DNA using ultrasound with Optison as compared with plasmid HGF DNA alone (blood pressure ratio of ischemic limb to normal limb of rabbits transfected with control vector was 0.63 ± 0.04; Figure 5d , P Ͻ 0.01). Finally, we examined the side-effects of intramuscular transfection of naked HGF plasmid using ultrasound with Optison. As expected, a single administration of HGF gene did not result in any acute toxicity including changes in clinical pathological indices, urinalysis parameters, and renal histopathological findings (data not shown). Histopathologic changes consisting of tubular degeneration were not present in the kidney. Other effects were also not observed including mononuclear cell infiltrates in multiple organs such as the spleen, liver and bone marrow. No alteration in histopathological, hematological or serum chemical findings was induced.
Discussion
In patients with critical limb ischemia, since there is no pharmacological treatment, amputation, despite its asso- ciated morbidity, mortality, and functional implications, 1, 29, 30 is often recommended as a solution to the disabling symptoms. [30] [31] [32] Recently, a novel therapeutic strategy using angiogenic growth factors to expedite and/or augment collateral artery development has entered the realm of treatment of ischemic diseases. The clinical utility of gene therapy using the VEGF gene has been recently reported for the treatment of critical limb ischemia and myocardial ischemia. [4] [5] [6] [7] [8] [9] [10] [11] Instead of VEGF, other angiogenic growth factors such FGF, HGF and a transcription factor for angiogenesis, HIF (hypoxiainducible factor), have been considered candidates for therapeutic angiogenesis as gene therapy for the treatment of patients with critical limb ischemia. [12] [13] [14] [15] [16] [17] [18] [19] [20] Although the feasibility of therapeutic angiogenesis using these angiogenic growth factors has been reported in experimental models and human clinical trials, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] there are still unresolved problems such as undesirable side-effects. Most clinical trials have employed intramuscular injection of naked plasmid DNA despite its low transfection efficiency. One of the distinguishing features of VEGF and HGF, the fact that the VEGF and HGF genes encode a secretory signal sequence, might be exploited as part of a strategy designed to accomplish therapeutic angiogenesis by gene transfer. Previous reports mentioned that site-specific transfection of rabbit ear arteries with a plasmid encoding the gene for human growth hormone, a secreted protein, yields local levels of human growth hor-mone equivalent to what has been considered to be in the physiologic range, despite that fact that immunohistochemical examination of the transfected tissue disclosed evidence of successful transfection in Ͻ1% of cells in the transfected arterial segment. 33 Thus, gene products that are secreted may have profound biological effects, even when the number of transduced cells remains low. In contrast, for genes such as bFGF or HIF that do not encode a secretory signal sequence, transfection of a much larger cell population might be required for that intracellular gene product to express its biological effects. In these cases, a more highly efficient transfection method would be necessary.
(b) Effect of transfection of human HGF plasmid on number of blood vessels as assessed by alkalinephosphatase staining at 5 weeks after transfection. (c) Effect of transfection of human HGF plasmid on percent increase in blood flow assessed by Doppler flow wire at 5 weeks after transfection. (d) Effect of transfection of human HGF plasmid on percent increase in ratio of blood pressure in ischemic hindlimb to that in (contralateral) non-ischemic hindlimb at 5 weeks after transfection. Control, rabbit transfected with control vector (1 mg/body); HGF, rabbit transfected with naked human HGF plasmid DNA (1 mg/body); HGF
Therefore, one might assume that higher transfection efficiency of angiogenic growth factors might increase the clinical utility of these treatments. Especially, this point is critical in utilizing non-secreted angiogenic growth factors (ie bFGF) or transcription factors promoting angiogenesis such as HIF. Currently, researchers are employing adenoviral gene transfer in clinical trials instead of naked plasmid DNA. However, the potential toxicity of adenovirus such as strong immunogenicity is well known. Of particular importance, the deleterious side-effects of adenovirus were reported in 1999. 28 Therefore, it is critical to develop a novel safe gene transfer method with high efficiency. From this viewpoint, we have focused on the plasmid DNA-based gene transfer method, since the plasmid DNA transfer method is apparently the most safe. To increase the transfection efficiency, we have modified ultrasound-mediated plasmid DNA transfection. Recently, the transfection efficiency of plasmid DNA was increased by ultrasound in cultured cells. [34] [35] [36] Consistent with previous reports, [34] [35] [36] the present study revealed a marked increase in transfection efficiency using ultrasound. Nevertheless, the degree of increased efficiency was still not enough. This observation is consistent with the previous report that ultrasound induced cell-membrane porosity. 37 Thus, we further modified ultrasound-mediated plasmid DNA transfection using echo contrast microbubble. The present study confirmed the previous observation that, ultrasound exposure in the presence of microbubble echo-contrast agents enhances acoustic, cavitation and is associated with approximately 300-fold increments in transgene expression after, naked DNA transfection in in vitro experiments. 38 Of importance, plasmid DNA transfection using ultrasound was markedly improved by a microbubble enhancer, Optison. The increase in transfection efficiency might be due to the appearance of transient holes in the cell membrane caused by spreading of the bubbles. A similar phenomenon was observed in thrombolysis by means of ultrasound. 39 It was reported that the presence of echo-contrast agents such as albumin microbubbles, which lowered the threshold of acoustic cavitation production, induced further acceleration of thrombolysis by ultrasound energy. 39 Optison is an ultrasound contrast agent, consisting of gas-filled microspheres surrounded by a solid shell of heat-denatured human albumin, different from other contrast agents. 40 These characteristics may help the increase in transfection efficiency. In addition, we optimized ultrasound-Optison-mediated plasmid DNA transfer into skeletal muscle in vivo. These data indicate an important role for acoustic cavitation in the effects of USE.
Given the efficient transfection of intramuscular plasGene Therapy mid DNA injection using ultrasound with Optison, we finally examined the activity of angiogenesis in a rabbit model. As expected, the angiographic score, capillary density, blood flow and ratio of blood pressure of the ischemic to non-ischemic hindlimb were significantly increased in rabbits transfected with human HGF plasmid DNA using ultrasound with Optison as compared with plasmid DNA alone. These data clearly demonstrate the clinical utility of therapeutic angiogenesis based upon plasmid DNA-mediated transfer. What is the clinical relevance of this efficient gene transfer method based upon plasmid DNA using ultrasound with Optison? First, it is possible to decrease the amount of plasmid DNA, thereby decreasing the potential cost. Second, it is possible to achieve efficient transfection without a viral vector. To avoid a viral gene transfer method, such as by means of adenovirus, may increase the safety and open up a wide variety of targeted diseases for gene therapy. Third, further modification of delivery tools, such as a catheter with ultrasound, may expand the utility of the present modification to the transfection into blood vessels, ovary or other organs. Fourth, as expected, in vivo study demonstrated no apparent toxicity in rabbits.
Overall, the present studies demonstrated a novel safe and efficient nonviral gene transfer method into cultured cells and skeletal muscle. A novel therapeutic strategy by means of HGF plasmid DNA using low intensity ultrasound with Optison to stimulate angiogenesis may be useful in reducing the symptoms of critical limb ischemia in clinical practice without a viral vector. In addition, stimulation of new vessel formation by angiogenic growth factors by means of plasmid DNA is likely to create new therapeutic options in angiogenesis-dependent conditions such as wound healing, inflammatory diseases, ischemic heart disease, myocardial infarction and peripheral arterial disease. Ultrasound can be focused upon almost any organ and hence this approach holds promise as a mean to deliver targeted gene therapy in many other clinical situations.
Materials and methods
In vitro experiments
Cell culture: Human skeletal muscle cells (passage 5) were obtained from Clonetics (San Diego, CA, USA), and cultured in modified MCDB131 medium supplemented with 5% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 ng/ml epidermal growth factor, 2 ng/ml bFGF and 1 M dexamethasone in the standard fashion. Cells were incubated at 37‫ؠ‬C in a humidified atmosphere of 95% air-5% CO with medium changes every 2 days.
Construction of plasmids:
To produce an HGF expression vector, human HGF cDNA (2.2 kb) was inserted into a simple eukaryotic expression plasmid that utilizes the cytomegalovirus (CMV) promoter/enhancer. 12, 18 This promoter/enhancer has been used to express reporter genes in a variety of cell types and can be considered to be constitutive. Downstream from the HGF cDNA is the SV40 polyadenylation sequence. The vector used as a control was CMV expression vector plasmid, which did not contain HGF cDNA. We obtained luciferase and ␤-galactosidase gene expression vectors driven by SV40 promoter from a commercial source (Promega, Madison, WI, USA).
Analysis of luciferase activity:
Firefly luciferase activity was measured using a luciferase assay system (PicaGene; Toyo-Inki, Tokyo, Japan). 41 Cells were harvested at 3 days after transfection of luciferase gene using 'naked' plasmid alone, or 'naked' plasmid using ultrasound with or without Optison (Molecular Biosystems, San Diego, CA, USA). Measurements of the luminescent reaction were started at 5 s after addition of the sample. Counting lasted for 10 s, and the count in 10 s was used for calculation of luciferase activity.
In vitro transfection of plasmid DNA: Cells were inoculated on day 0, and grown to confluence in 5% calf serum. After confluence was reached, the medium was changed to fresh DSF (defined serum-free medium) supplemented with insulin (5 × 10 -7 M), transferrin (5 mg/ml), and ascorbate (0.2 mM). Plasmid DNA (20 g) was added to the dishes. Then, cells were treated with ultrasound for min (1 MHz, 2.5 W/cm 2 ) at 37‫ؠ‬C. To enwrap plasmid DNA in Optison, Optison was added to plasmid solution, mixed and left for 30 s. After incubation, the medium was changed to fresh medium containing 0.5% serum.
In vivo experiments
In vivo gene transfer using direct intramuscular injection approach: Sprague-Dawley rats (400-500 g; Charles River Breeding Laboratories, Wilmington, MA, USA) were anesthetized with an intraperitoneal injection of sodium pentobarbital (0.1 ml/100 mg). 'Naked' luciferase gene, (20 g/body) or control vector (20 g/body) was carefully injected directly into the center of pretibial muscle of the right hindlimb of rats with a 27 G needle (Terumo, Atsugi, Japan). Ultrasound treatment was performed for 1 min at 1 MHz, 2.5 W/cm 2 ( Figure 2a) . A mixture of plasmid DNA with Optison was performed by gentle hand shaking for 1 min.
Analysis of luciferase activity: Firefly luciferase activity was measured using a luciferase assay system (PicaGene; Toyo-Inki). Rats were killed 2 days after transfection of luciferase gene by direct injection of 'naked' plasmid into the hindlimb. Tissue samples (200 mg around the injection site) were rapidly frozen in liquid nitrogen, and homogenized in lysis buffer. The tissue lysates were briefly centrifuged (3000 r.p.m. 10 min), and 20 l of supernatant was mixed with 100 l of luciferase assay reagents. Measurement of the luminescent reaction was started 5 s after addition of the sample. Counting lasted for 10 s, and the count in 10 s was used as an index of luciferase activity. 41 Immunohistochemical staining of ␤-galactosidase: Immunohistochemical staining of ␤-galactosidase was performed using the avidin-biotin system. 29 Rats were killed 5 days after transfection of ␤-galactosidase gene by direct injection of 'naked' plasmid with ultrasound and Optison into the rat hindlimb. Sections were dewaxed, rehydrated, and incubated with PBS containing 0.3% hydrogen peroxide to reduce endogenous peroxidase activity. The sections were then incubated with primary antibody (anti-␤-galactosidase monoclonal antibody, Promega) or lectin, diluted in PBS with 10% horse serum, at room temperature for 60 min. After washing three times in Trisbuffered saline containing 2% horse serum, speciesappropriate biotinylated secondary antibody was applied, followed by avidin-biotin peroxidase complex (Vectastain ABC kit, PK 6100; Vector Laboratories, CA, USA). Omission of the primary antibody and staining with type-and class-matched irrelevant immunoglobulin served as a negative control for each antibody.
Rabbit ischemic hindlimb model:
The physiological response to transfection of human HGF vector was also investigated in the rabbit ischemic hindlimb model, described in a previous report. 12, 42, 43 Briefly, male New Zealand White rabbits (3.5 to 4.0 kg) (Kitayama Rabes, Kyoto, Japan) were used. Four separate injections of 250 g human HGF vector (total 1 mg) locally (intramuscularly into the pretibial muscle of ischemic limb) were performed approximately 2-4 cm below the skin. Ten days after surgery (day 10) and after measurement of baseline body weight as well as baseline noninvasive and invasive measurements of hemodynamic parameters, the animals received an intramuscular injection of human HGF 'naked' plasmid vector or control plasmid lacking HGF gene (1 mg total) using ultrasound with or without Optison through a 27-gauge needle (Terumo), as described above.
Quantitative angiography: The angiographic luminal diameter of the internal iliac artery in the ischemic limb at baseline and after transfection was determined on day 0 and 30 by previously described techniques. 12, 42, 43 Briefly, morphometric analysis of collateral vessel development in the ischemic limb was performed in 4-s angiograms recorded after injection of contrast medium into the internal iliac artery. A grid with 20-mm spaces was placed over the angiogram in the region of the medial thigh. The number of contrast-opacified arteries crossing over circles and the total number of lines encompassing the medial thigh area were counted in a blinded fashion. The angiographic score was calculated as the ratio of overlying opacified arteries divided by the total number of lines in the ischemic thigh. This angiographic score reflects vascular density in the medial thigh.
Intra-arterial Doppler guidewire measurement of blood flow: Blood flow was quantified in vivo before selective internal iliac angiography in New Zealand White rabbits using a 0.018-inch Doppler guidewire (Cardiometrics, CA). 12, 41, 42 The wire was advanced via a 3-F infusion catheter positioned at the origin of the common iliac artery to the proximal segment of the iliac artery supplying the ischemic limb. Maximum APV (average peak velocity) was recorded at rest. APV was recorded after bolus injection of 2 mg papaverine or nitroglycerine. After completing identical measurements in the normal limb, selective internal iliac angiography was performed as described above.
The angiographic luminal diameter of the internal iliac artery in the ischemic limb and of the external iliac artery in the normal limb were determined using an automated edge-detection system as previously described. 12, 42, 43 The film selected for analysis was scanned with a high resolution video camera; the signal produced by the video camera was digitized and displayed on a video monitor (Laser Scan Image Comm, Santa Clara, CA, USA). Center-lines were traced manually for a 10-mm long segment beginning immediately distal to the tip of the Doppler wire. The contents were subsequently detected automatically on the basis of the weighted sum of the first and second derivative functions applied to the digitized brightness information. The vascular diameter was then measured at the site of the Doppler sample volume (5 mm distal to the wire top). The cross-sectional area was calculated assuming a circular lumen. Dopplerderived flow was calculated as previously described. 12, 41, 42 Measurement of blood pressure: Calf blood pressure was measured using a Doppler flowmeter. The pulse of the posterior tibial artery was identified using a Doppler probe, and the systolic blood pressure in both limbs was determined using standard techniques. 12, 42, 43 The calf blood pressure ratio for each rabbit was defined as the ratio of systolic pressure of the ischemic limb to that of the normal limb.
Statistical analysis
All values are expressed as mean ± s.e.m. Analysis of variance with subsequent Duncan's test was used to determine the significance of differences in multiple comparisons. Differences with a P value less than 0.05 were considered significant.
